Skip to main content
. 2022 Apr 8;10:goac009. doi: 10.1093/gastro/goac009

Figure 2.

Figure 2.

Regulation of gut microbiota–bile acid–farnesoid X receptor (FXR) axis to improve type 2 diabetes. Metformin reduces the abundance of B. fragilis and inhibits bile salt hydrolase (BSH) activity. These changes can further increase levels of GUDCA (endogenous FXR antagonists) and suppress the FXR signaling. It shows beneficial effects on metabolic diseases dependent on intestinal FXR inhibition.